San Francisco, California, Nov 15, 2017: The global immunomodulators market is estimated to expand at a fast pace on account of several reasons including growing adoption of TNF alpha inhibitors and B cell inhibitors, rising adoption of monoclonal antibodies, advancements in diagnostic tools, presence of strong pipeline portfolio, and innovative technologies, states TMR Research in its latest report. The report is titled “Immunomodulators Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025.” The development of novel therapies using innovative technologies will also boost the growth of the global immunomodulators market.
According to the report, the global immunomodulators market is anticipated to witness an exponential growth during the forecast period from 2017 to 2025 on account of the heightened increase in the number of people suffering from chronic diseases such as allergic conditions, asthma, multiple sclerosis, and cancer. What favors the market additionally, is the early employment of immunomodulatory therapy for treating Crohn’s disease. Immunomodulator therapies are also emerging as promising alternatives on account of less organ rejection incidence and higher remission rate.
With growing incidences of multiple sclerosis, the generation of advanced biological response modifiers is also growing and this is benefiting the market for immunomodulators. Another factor that is boding well for the market is the fact that immunomodulators pose very less risk of side effects in comparison to the existing drugs available in the market. In addition to these factors, the presence of vast, unfulfilled and unmet clinical or medical needs, coupled with the need for alternative treatments for rheumatoid arthritis will emerge as key factors behind the extensive growth of the immunomodulators market.
On the basis of product, the global immunomodulators market is segmented into antibodies, antimetabolites, calcineurin inhibitors, and glucocorticoids; and immunostimulants such as antibodies and vaccines. By application the market for immunomodulators can be segmented into respiratory, HIV, and oncology. Some of the other applications of immunomodulators are Crohn’s disease, rheumatoid arthritis, and multiple sclerosis.
By geography, North America is expected to lead in the market for immunomodulators on account of the presence of a large population who are suffering from a variety of chronic ailments as well as the high awareness level among these patients about the available treatment options. Another factor which is favoring the growth of the immunomodulators market in North America is the initiatives taken by government as well as the presence of favorable medical reimbursement policies.
The leading players within the immunomodulators market include: Johnson & Johnson, Amgen, Inc., : F. Hoffmann-La Roche Ltd., Abbott, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck & Co., Inc., and Biogen.
Get Sample Copy of this Report